The IQ Microphysiological Systems (IQ MPS) Affiliate is announcing the public availability of the MPS Training Course (www.iqmps.org/course). Developed in collaboration with FDA/CDER as part of a public–private partnership established in 2020, and with perspective from the European Commission Joint Research Centre (EU-JRC), this training introduces how pharmaceutical scientists design, characterize, qualify, and apply complex in vitro models (CIVM)—including organoids, microphysiological systems (MPS), and organ-chips—to address questions in efficacy, ADME, and preclinical safety.

The course provides practical instruction on cell sourcing and model construction, experimental design, biological endpoints, and reproducibility considerations, along with real-world case studies demonstrating how CIVM are used to generate decision-enabling data for drug development.

Initially designed to support regulatory familiarity with and consistent interpretation of CIVM-derived data in regulatory filings, the course has since been accessed by regulatory assessors internationally, including participants from FDA, EMA, MHRA, PMDA, and CDE. It is now available to all stakeholders to facilitate broader dialogue on the harmonization of scientific and regulatory practices for qualifying these tools for various regulatory contexts of use.

Register for the course here: www.iqmps.org/course